|
26 Apr 2021 |
Chemomab Announces Enrollment of First Patient in Phase 2a Study of CM-101 in Non-Alcoholic Steatohepatitis (NASH)
|
|
26 Apr 2021 |
Biond Biologics Announces First Patient Dosed in Phase 1 Clinical Trial of BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
|
|
26 Apr 2021 |
Pieris Pharmaceuticals and Boston Pharmaceuticals Enter into an Exclusive Worldwide Product License for PRS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific
|
|
26 Apr 2021 |
Tagrisso recommended for approval in the EU by CHMP for the adjuvant treatment of patients with early-stage EGFR-mutated lung cancer
|
|
26 Apr 2021 |
Selumetinib recommended for approval in the EU by CHMP as the first medicine for paediatric patients with neurofibromatosis type 1 and plexiform neurofibromas
|
|
26 Apr 2021 |
Nirsevimab MELODY Phase III trial met primary endpoint of reducing RSV lower respiratory tract infections in healthy infants
|
|
24 Apr 2021 |
CHMP recommends EU approval of Roche’s ENSPRYNG (satralizumab) for adults and adolescents with neuromyelitis optica spectrum disorder (NMOSD)
|
|
24 Apr 2021 |
INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800
|
|
24 Apr 2021 |
Johnson & Johnson Single-Shot COVID-19 Vaccinations to Resume in the U.S. for All Adults Aged 18 and Older Following CDC and FDA Decision
|
|
24 Apr 2021 |
LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis
|
|
24 Apr 2021 |
AbbVie Receives Positive CHMP Opinion for VENCLYXTO® (venetoclax) as a Combination Regimen for Adult Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
|
|
24 Apr 2021 |
Bristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) Plus Yervoy (ipilimumab) as First-Line Treatment for Unresectable Malignant Pleural Mesothelioma
|
|
24 Apr 2021 |
Bristol Myers Squibb Receives Positive CHMP Opinion for Onureg® (azacitidine tablets; CC-486) as Frontline Oral Maintenance Therapy for Adults with Acute Myeloid Leukemia in First Remission
|
|
24 Apr 2021 |
Bristol Myers Squibb Presents Positive Data from Two Pivotal Phase 3 Psoriasis Studies Demonstrating Superiority of Deucravacitinib Compared to Placebo and Otezla® (apremilast)
|
|
24 Apr 2021 |
ADC Therapeutics Announces FDA Approval of ZYNLONTA™ (loncastuximab tesirine-lpyl) in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
|
|
23 Apr 2021 |
UCB’s zilucoplan shows no relevant effect in immune-mediated necrotizing myopathy (IMNM)
|
|
23 Apr 2021 |
FDA grants accelerated approval for GSK’s JEMPERLI (dostarlimab-gxly) for women with recurrent or advanced dMMR endometrial cancer
|
|
22 Apr 2021 |
Pharming announces enrolment of first patient in multicentre Phase IIb clinical trial of RUCONEST® for the prevention of acute kidney injury after myocardial infarction
|
|
22 Apr 2021 |
Yumanity Therapeutics’ YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy Volunteers
|
|
22 Apr 2021 |
Toripalimab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer Reached Primary Endpoints in Phase III Clinical Study
|
